Drug Development

J&J dumps a failed PhIII antibiotic program picked up in Actelion buyout

J&J is washing its hands of the Phase III Clostridium difficile-associated diarrhea program for the antibiotic cadazolid.

Jean-Paul Clozel

The pharma giant obtained rights to the antibiotic in their $30 billion buyout of Actelion. But as the deal was being completed, cadazolid floundered — hitting the goal posts in one study but missing in another — after recruiting 1,263 patients to compare 250 mg of cadazolid twice daily against 4 daily doses of 125 mg vancomycin.

Typically the FDA requires a success in two pivotal studies to warrant an approval — a standard that has bedeviled a variety of small players like Tetraphase. Last June the execs at Actelion, who were taking some assets and spinning out into a new company called Indorsia, said they’d do a final analysis and determine what to do next.

J&J wrote it off in their quarterly release, saying only that they would discontinue the Phase III program.

J&J won the deal to buy Actelion last year after Sanofi managed to tick off Actelion CEO Jean-Paul Clozel. The cadazolid pact was put in place alongside a partnership on ponesimod, the more closely-watched drug.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 35,600+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Research Scientist - Disease Biology
Recursion Pharmaceuticals Salt Lake City, UT
Senior Scientist - Predictive Pharmacology
Recursion Pharmaceuticals Salt Lake City, UT
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA
Director of Marketing
twoXAR Mountain View, CA

Visit Endpoints Careers ->